1 recruiting, 1 terminated. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
Follow Outpace Bio, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. OPB-201 - Endometrial Cancer Recurrent, Endometrial Cancer | Phase 1 | Recruiting | Outpace Bio, Inc. | 30 | 2026-06-30 | 2026-10-26 |
| A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer OPB-101 - Ovarian Cancer Recurrent, Ovarian Cancer | Phase 1 | Terminated | Outpace Bio, Inc. | 3 | 2025-06-16 | 2026-10-26 |
Ovarian Neoplasms (2) · Endometrial Neoplasms (1)
United States (2)